[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemorrhoidal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemorrhoidal-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,79,107],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100644102","female-sexual-function-after-surgery-for-benign-perianal-diseases-100644102",false,"NCT07666035","Female Sexual Function After Surgery for Benign Perianal Diseases","Prospective Evaluation of Female Sexual Function Following Surgical Treatment of Benign Perianal Diseases: A Single-Center Observational Cohort Study","PERISEX","Inclusion Criteria:\n\n* Female patients aged 18-70 years\n* Sexually active during the previous 4 weeks\n* Diagnosed with chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula\n* Scheduled for surgical treatment according to routine clinical indications\n* Able to understand and complete study questionnaires\n* Willing to provide written informed consent\n\nExclusion Criteria:\n\n* Inflammatory bowel disease (Crohn's disease or ulcerative colitis)\n* Pregnancy\n* Postpartum period within the previous 12 months\n* Pelvic organ prolapse\n* Previous treatment for female sexual dysfunction\n* Current antidepressant medication use\n* Active psychiatric disorder\n* Gynecological malignancy\n* Previous pelvic radiotherapy\n* Inability or unwillingness to complete study questionnaires\n* Refusal to provide informed consent","FEMALE","18 Years","70 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","Benign perianal diseases such as chronic anal fissure, hemorrhoidal disease, and cryptoglandular anal fistula may negatively affect female sexual function through pain, bleeding, discharge, discomfort, and impairment in quality of life. Although improvement in male sexual function after surgery for benign anorectal disorders has been reported, data regarding female sexual function remain limited.\n\nThis prospective observational cohort study aims to evaluate changes in Female Sexual Function Index (FSFI) scores following surgical treatment of benign perianal diseases. Female patients undergoing surgery for chronic anal fissure, hemorrhoidal disease, or cryptoglandular anal fistula will be assessed preoperatively and at postoperative 3 and 6 months using the FSFI, Cleveland Clinic Incontinence Score (CCIS\u002FWexner), and Visual Analog Scale (VAS).\n\nThe primary objective is to determine whether female sexual function improves following surgical treatment. Secondary objectives include evaluating the relationship between symptom improvement, continence status, pain reduction, and changes in female sexual function.",[26,27,28],"Chronic Anal Fissure","Hemorrhoidal Disease","Cryptoglandular Anal Fistula",[28,26,27,30,31,32],"FSFI","Sexual Functions","Perianal Pain","NOT_YET_RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-26","ACTUAL",{"date":39,"type":22},"2026-08",{"date":41,"type":22},"2028-02",{"name":43,"class":44},"Gazi University","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100643992","phase-3-nimsai-herbal-for-grade-2-3-hemorrhoids-a-quadruple-blind-placebo-controlled-mechanistic-trial-100643992","NCT07669662","Nimsai Herbal for Grade 2-3 Hemorrhoids: A Quadruple-Blind Placebo-Controlled Mechanistic Trial","Quadruple-Blind, Placebo-Controlled, Parallel-Group Randomized Controlled Trial to Evaluate the Efficacy and Safety of Nimsai Herbal in Patients With Grade 2-3 Hemorrhoids","NAJ2","Inclusion Criteria:\n\n* Endoscopically confirmed Grade 2 or 3 internal hemorrhoids\n\nHistory of hemorrhoidal symptoms persisting for more than 6 weeks prior to screening\n\nAge 18 to 70 years inclusive at time of informed consent\n\nWillingness and ability to provide written informed consent\n\nWillingness and ability to comply with all study procedures, schedules, and follow-up requirements\n\nExclusion Criteria:\n\n* Diagnosis of Grade 1 or Grade 4 hemorrhoids\n\nAny known anorectal malignancy or suspicion of malignancy\n\nActive bleeding from sources other than hemorrhoids\n\nCurrently pregnant or lactating women, or women of childbearing potential not using effective contraception\n\nKnown hypersensitivity or allergy to any component of Nimsai Herbal or placebo\n\nSignificant systemic diseases including severe cardiovascular disease, severe renal impairment, severe hepatic dysfunction, or uncontrolled diabetes mellitus (HbA1c \\> 9%)\n\nAny medical or psychiatric condition that might compromise participant safety or data integrity\n\nParticipation in another interventional clinical trial within 30 days prior to screening\n\nUse of concurrent treatments for hemorrhoids within 7 days prior to screening\n\nHistory of hemorrhoidectomy or other invasive hemorrhoid procedures within the last 6 months","ALL",{"count":55,"type":22},50,"INTERVENTIONAL",[58],"PHASE3","This randomized, quadruple-blind, placebo-controlled clinical trial evaluates the efficacy and safety of Nimsai Herbal, a proprietary oral phytotherapeutic formulation, in 50 participants aged 18-70 years with endoscopically confirmed Grade 2-3 internal hemorrhoids. Participants will be randomly assigned in a 1:1 ratio to receive either Nimsai Herbal (600 mg) or identical placebo once daily for 10 consecutive days. The primary endpoint is hemorrhoid regression at Day 10, defined as either a reduction in Goligher grade or a ≥75% reduction in composite hemorrhoid severity score. Secondary endpoints include change in symptom severity measured by Visual Analog Scale and complete symptom resolution rate. The study is designed as a mechanistic signal-detection investigation based on the War-Drill Model, which posits venous congestion as the primary initiating event in hemorrhoid pathogenesis.",[61,27],"Hemorrhoid",[63,64,65,66,67,68],"venous stasis","War-Drill Model","Parola Phenomenon","phytotherapy","Nimsai Herbal","quadruple-blind","2026-06-20",{"date":71,"type":37},"2026-06-25",{"date":73,"type":22},"2026-06-22",{"date":75,"type":22},"2026-07-02",{"name":77,"class":44},"Nimsai Academia",1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":78},"100632980","clinical-outcomes-after-laser-hemorrhoidoplasty-100632980","NCT07520734","Clinical Outcomes After Laser Hemorrhoidoplasty","Clinical Outcomes, Pain Scores, and Patient Satisfaction in Patients Undergoing Laser Hemorrhoidoplasty: A Prospective Observational Study","LHP","Inclusion Criteria:\n\n* Age 18 years or older\n* Symptomatic internal hemorrhoidal disease\n* Scheduled to undergo laser hemorrhoidoplasty\n* Willingness to participate and provision of informed consent\n\nExclusion Criteria:\n\n* Grade IV hemorrhoidal disease\n* Acute thrombosed hemorrhoids\n* Additional anorectal pathology such as anal fissure, fistula, or perianal abscess\n* History of inflammatory bowel disease or colorectal malignancy\n* Previous major anal surgery'",{"count":88,"type":22},60,"This single-center prospective observational study aims to evaluate clinical outcomes, postoperative pain scores, complications, and patient satisfaction in adults undergoing laser hemorrhoidoplasty for symptomatic internal hemorrhoidal disease. Additional objectives are to assess the relationship between hemorrhoid stage, dominant presenting symptoms, operative technical details, and postoperative outcomes. No study-specific intervention beyond routine clinical care and follow-up will be performed.",[27,91],"Internal Hemorrhoids",[93,94,95,96],"Laser hemorrhoidoplasty","Hemorrhoidal disease","Patient satisfaction","Visual Analog Scale","2026-04-02",{"date":99,"type":37},"2026-04-09",{"date":101,"type":22},"2026-04-01",{"date":103,"type":22},"2027-04-01",{"name":105,"class":106},"Sanliurfa Education and Research Hospital","OTHER_GOV",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":17,"minAge":115,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":56,"phases":118,"briefSummary":120,"conditions":121,"keywords":123,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":78},"100606440","a-clinical-study-on-alleviating-hemorrhoids-related-symptoms-of-pelvic-radiation-therapy-100606440","NCT07175584","A Clinical Study on Alleviating Hemorrhoids-related Symptoms of Pelvic Radiation Therapy","Anal Canal-Sparing Technique During Postoperative Pelvic Radiation Therapy for Cervical Cancer Patients to Reduce Hemorrhoids-related Symptoms: A Multicenter Randomized Clinical Trial","ACS-RT","Inclusion Criteria:\n\n* Treated with hysterectomy (including total abdominal hysterectomy, vaginal hysterectomy, radical hysterectomy, or laparoscopically assisted vaginal hysterectomy) within 6 weeks prior to study initiation.\n* Histologically proven diagnosis of cervical carcinoma, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* Requirement for postoperative adjuvant concurrent chemoradiotherapy (CCRT).\n* Age \\> 18 years.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n* History of hemorrhoids prior to radiotherapy, with no hemorrhoid-related symptoms for at least 4 weeks before radiation therapy initiation.\n* Abdominal\u002Fpelvic MRI, chest CT, or PET-CT performed before surgery or study enrollment to confirm staging and exclude patients with distant metastasis.\n* Adequate bone marrow, renal, and hepatic function.\n* Agreement to undergo anal canal MRI before radiation therapy initiation.\n* Patient must provide study-specific informed consent form (ICF) prior to study entry.\n\nExclusion Criteria:\n\n* Cervical cancer patients who do not meet the criteria for adjuvant radiation therapy.\n* Without a confirmed history of hemorrhoids.\n* Patients contraindicated for MRI (e.g., due to incompatible metallic implants, claustrophobic syndrome, or other contraindications).\n* Patients who refuse to undergo anal canal MRI.\n* Patients with radiographically visible residual disease post-surgery requiring boost during the pelvic EBRT.\n* History of other malignancies.\n* Prior pelvic radiotherapy resulting in overlapping radiation fields.\n* History of allergic reaction to platinum-based chemotherapy agents.\n* Severe and\u002For active comorbidities precluding tolerance of concurrent chemoradiotherapy.","19 Years",{"count":117,"type":22},300,[119],"NA","The goal of this clinical trial is to reduce the acute hemorrhoids-related symptoms for cervical cancer patients with hemorrhoids who need postoperative pelvic radiation therapy, including prolapse, local burning, bleeding, perianal pain, and other perianal discomforts.\n\nThe main questions it aims to answer are:\n\nWill anal canal-sparing technique improve the quality of life for cervical cancer patients with hemorrhoids during pelvic radiation therapy? Will the radiation dose exposure to anal canal be reduced through anal canal-sparing technique?\n\nResearchers will compare the aggravation of radiation-induced hemorrhoids-related symptoms occurring from the initiation of pelvic radiation therapy until 4 weeks after its completion. Conventional postoperative treatment regimens will not be changed and researchers will only reduce the irradiated dose to anal canal which should be protected during pelvic radiation therapy.\n\nParticipants will be randomly assigned with equal probability (1:1 ratio) to either: control group (conventional postoperative pelvic radiation therapy) and intervention group (anal canal-sparing pelvic radiation therapy), in either combined with brachytherapy or not. Following randomization, participants will not be informed of their group assignment until completion of the follow-up period.\n\nNotice: The treatment efficacy will not be compromised by group assignment. No additional treatment-related adverse effects will occur due to study participation. The intervention group may potentially mitigate radiotherapy-induced adverse effects.",[27,122],"Cervical Cancer Radiation Complications",[124,125,126],"cervical cancer","hemorrhoidal disease","pelvic radiation therapy","2025-09-16",{"date":129,"type":37},"2025-09-22",{"date":131,"type":22},"2025-09-29",{"date":133,"type":22},"2027-12-31",{"name":135,"class":44},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]